FDA clears Laguna’s LGNA-100 for pediatric leukemia study
Laguna Biotherapeutics said the US Food and Drug Administration has cleared its investigational new drug application for LGNA-100, opening the way for a first-in-human Phase 1 study in pediatric and young adult patients with high-risk acute leukemias and myelodysplastic syndromes after αβ-depleted hematopoietic stem cell transplantation. The company describes LGNA-100 as a first-in-class, attenuated live bacterial immunotherapy derived from Listeria monocytogenes and built on its QUAIL platform, with the goal of expanding and activating endogenous γδ T cells to reduce post-transplant relapse risk. Laguna announced the clearance on April 29, 2026, and said the open-label, single ascending dose study will test intravenous LGNA-100 for safety, tolerability, and proof of mechanism. (globenewswire.com)
Why it matters: While this is a human oncology development, it reflects a broader translational trend veterinary professionals are already watching closely: engineered microbial and cell-directed immunotherapies are moving beyond conventional checkpoint and CAR-T approaches toward therapies designed to reshape innate immune responses. Laguna’s scientific rationale is that γδ T cells may provide graft-versus-leukemia activity without driving graft-versus-host disease after transplant, a concept the company and its clinical advisors say could offer a differentiated path in high-risk pediatric leukemia, where relapse after transplant remains a major unmet need. UC Berkeley researchers tied to the platform have also described the underlying work as the product of decades of Listeria immunology research, with preclinical data published earlier this year supporting a safer, reprogrammed bacterial approach intended to preserve immune activation while reducing pathogenicity. (globenewswire.com)
What to watch: Next comes trial initiation, early enrollment details, and any first safety or biomarker readouts that show whether LGNA-100 can expand γδ T cells in patients as predicted. (globenewswire.com)